In this project, we will evaluate a novel therapeutic strategy for the treatment of T-ALL, an aggressive subtype of leukemia. Using novel immunocytokines, we aim to combine direct targeting of the leukemia cells with indirect stimulation of the immune system. In that way, we believe that we can reduce adverse side effects that are associated with current chemotherapy regimens, and build an immunological memory that will prevent putative disease relapse.